Management of metastatic prostatic cancer
- PMID: 3054907
Management of metastatic prostatic cancer
Abstract
Since 1973, two studies covering a 10-year period in the United States were conducted by the Commission on Cancer of the American College of Surgeons. Participating hospitals from over 1,200 institutions contributed over 70,000 cases to this report and review. These hospitals represent nearly 80% of the newly diagnosed cancer cases in the United States annually at the present time. From these studies, certain confirmations of trends in the general treatment at the local level for prostate cancer were observed. For example, there was an overall reduction in the number of patients receiving hormone treatment for localized prostate cancer. At the same time during this study, more patients received external radiotherapy or surgery for the localized lesions. Disseminated newly diagnosed prostate cancer was equally treated by orchiectomy or diethylstilbestrol. A distinct relationship was observed between the grade of the tumor and the stage. In the latter 5-year period of this observation time, more patients were graded by pathologists upon diagnosis at their community hospital than previously. This exceeded over 85% and represented a remarkable conversion. The more frequent grading system used was that employed and described by Gleason. More extensive use of bone scans over a 10-year period on initial evaluation was also reported. Other patterns of care relating to national trends and incidences will be described. The American black male has the highest incidence of prostate cancer in the world. Grade for grade, stage for stage, these men do less well regardless of treatment than their white counterparts. (Schmidt, 1986) These factors will have to be further studied.
Similar articles
-
Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.Scand J Urol Nephrol. 2006;40(4):265-71. doi: 10.1080/00365590600750110. Scand J Urol Nephrol. 2006. PMID: 16916765
-
Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. doi: 10.1016/j.ijrobp.2005.03.029. Epub 2005 May 31. Int J Radiat Oncol Biol Phys. 2005. PMID: 15925452
-
[Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].Actas Urol Esp. 1997 Sep;21(8):724-36. Actas Urol Esp. 1997. PMID: 9412221 Spanish.
-
Combined androgen blockade: the gold standard for metastatic prostate cancer.Eur Urol. 1997;32 Suppl 3:70-7. Eur Urol. 1997. PMID: 9267789 Review.
-
[PSA and follow-up after treatment of prostate cancer].Prog Urol. 2008 Mar;18(3):137-44. doi: 10.1016/j.purol.2007.12.010. Epub 2008 Apr 18. Prog Urol. 2008. PMID: 18472065 Review. French.
Cited by
-
Cell biology of liver endothelial and Kupffer cells.Gut. 1994 Nov;35(11):1509-16. doi: 10.1136/gut.35.11.1509. Gut. 1994. PMID: 7828963 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical